Recombinant Anti-CD64 x Anti-HER2 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD64 antibody variable domain is fused to CH1 and the other scFv from an anti-HER2 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors therapy.